Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis.

ABSTRACT:

Background

Poly (ADP-ribose) polymerase inhibitors (PARPi) are linked to thrombotic events, but the thrombosis risk in various cancers is unclear. This study evaluates the incidence and risk of venous thromboembolic events (VTEs) in patients with solid tumors treated with PARPi.

Materials and methods

This meta-analysis included randomized controlled phase II and III clinical trials in which patients with prostate, breast, ovarian, pancreatic, glioblastoma, small-cell lung (SCLC), and non-small-cell lung (NSCLC) cancers were treated with PARPi as monotherapy or in combination. The primary endpoint was to assess the frequency and risk of VTEs in patients treated with PARPi, while the secondary endpoint compared the incidence across different cancer subtypes.

Results

The

SUBMITTER: Yazgan SC 

PROVIDER: S-EPMC12513207 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature